We are analyzing https://link.springer.com/article/10.1007/s10014-013-0174-9.

Title:
The mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma | Brain Tumor Pathology
Description:
Glioblastoma (GBM) is one of the most lethal malignancies in humans, and novel therapeutic strategies are urgently required for its treatment. Tyrosine kinases (TKs) play a pivotal role in intercellular signal transduction and regulate crucial processes of tumor cell biological activities in GBM. This information provides the basis for the molecular target therapies for GBMs. TK inhibitors (TKIs) are expected to be effective therapeutic strategies. However, one important limitation is that GBMs exhibit marked resistance to the TKIs currently available, yet the mechanisms underlying TKI resistance have not been fully characterized. In the current review, we will address the varieties of chemoresistance mechanisms against TKIs in GBM. The mechanisms responsible for TKI refractoriness in GBMs are divided into 2 aspects. The first includes tumor-related concerns, such as a lack of target expression, the multiplicity of targets, redundancy, the appearance of resistant cells, and tumor changes in characteristics. The second includes drug-related concerns, such as inefficient drug effects, delivery, pharmacokinetics, and intolerable side effects. A better understanding of these mechanisms is needed to develop accurate tests to predict the lack of response to TKIs and for developing novel approaches aimed at overcoming the resistance to TKIs.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

pubmed, article, google, scholar, cas, cancer, glioblastoma, central, tyrosine, kinase, glioma, tumor, resistance, inhibitors, nakada, cell, drug, cells, receptor, oncol, egfr, brain, kinases, access, clin, inhibitor, erlotinib, privacy, cookies, content, malignant, kita, watanabe, therapeutic, role, tkis, response, recurrent, prados, phase, patients, science, protein, abcg, breast, invasion, information, publish, research, search,

Topics {✒️}

yutaka hayashi & jun-ichiro hamada pten/pi3k/akt pathway regulates month download article/chapter dna damage response tumor-specific peptide vaccination mesenchymal-epithelial transition inhibitor p-glycoprotein-mediated efflux includes drug-related concerns includes tumor-related concerns egfr gene amplification—rearrangement met-amplified recurrent glioblastoma receptor tyrosine kinases full article pdf targeting tyrosine kinases human glioblastoma multiforme tyrosine kinase inhibitors privacy choices/manage cookies rich jn egfr kinase inhibitors glioblastoma defines subpopulations glioma tumor stem effective therapeutic strategies friedman hs invasive glioma cells blood–brain barrier article nakada inefficient drug effects normalizes tumor vasculature cancer stem cells integrated genomic analysis haas-kogan da abcg2 multidrug transporter individualized targeted therapy european economic area intercellular signal transduction regulate crucial processes develop accurate tests variable proportions reflective abc multidrug transporters mellinghoff ik john-williams ls ethyl]amino}methyl atp-binding cassette individual tumor heterogeneity restrict brain accumulation tyrosine kinases article log phase ii study short-term treatment conditions privacy policy

Questions {❓}

Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A (2012) ‘Go or grow’: the key to the emergence of invasion in tumour progression?
Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J (2013) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: fact or fiction?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma
         description:Glioblastoma (GBM) is one of the most lethal malignancies in humans, and novel therapeutic strategies are urgently required for its treatment. Tyrosine kinases (TKs) play a pivotal role in intercellular signal transduction and regulate crucial processes of tumor cell biological activities in GBM. This information provides the basis for the molecular target therapies for GBMs. TK inhibitors (TKIs) are expected to be effective therapeutic strategies. However, one important limitation is that GBMs exhibit marked resistance to the TKIs currently available, yet the mechanisms underlying TKI resistance have not been fully characterized. In the current review, we will address the varieties of chemoresistance mechanisms against TKIs in GBM. The mechanisms responsible for TKI refractoriness in GBMs are divided into 2 aspects. The first includes tumor-related concerns, such as a lack of target expression, the multiplicity of targets, redundancy, the appearance of resistant cells, and tumor changes in characteristics. The second includes drug-related concerns, such as inefficient drug effects, delivery, pharmacokinetics, and intolerable side effects. A better understanding of these mechanisms is needed to develop accurate tests to predict the lack of response to TKIs and for developing novel approaches aimed at overcoming the resistance to TKIs.
         datePublished:2014-01-08T00:00:00Z
         dateModified:2014-01-08T00:00:00Z
         pageStart:198
         pageEnd:207
         sameAs:https://doi.org/10.1007/s10014-013-0174-9
         keywords:
            Glioma
            Tyrosine kinase inhibitor
            Chemoresistance
            Neurosurgery
            Neurology
            Pathology
            Oncology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10014-013-0174-9/MediaObjects/10014_2013_174_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10014-013-0174-9/MediaObjects/10014_2013_174_Fig2_HTML.gif
         isPartOf:
            name:Brain Tumor Pathology
            issn:
               1861-387X
               1433-7398
            volumeNumber:31
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Japan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mitsutoshi Nakada
               affiliation:
                     name:Kanazawa University
                     address:
                        name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daisuke Kita
               affiliation:
                     name:Kanazawa University
                     address:
                        name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Takuya Watanabe
               affiliation:
                     name:Kanazawa University
                     address:
                        name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yutaka Hayashi
               affiliation:
                     name:Kanazawa University
                     address:
                        name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jun-ichiro Hamada
               affiliation:
                     name:Kanazawa University
                     address:
                        name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma
      description:Glioblastoma (GBM) is one of the most lethal malignancies in humans, and novel therapeutic strategies are urgently required for its treatment. Tyrosine kinases (TKs) play a pivotal role in intercellular signal transduction and regulate crucial processes of tumor cell biological activities in GBM. This information provides the basis for the molecular target therapies for GBMs. TK inhibitors (TKIs) are expected to be effective therapeutic strategies. However, one important limitation is that GBMs exhibit marked resistance to the TKIs currently available, yet the mechanisms underlying TKI resistance have not been fully characterized. In the current review, we will address the varieties of chemoresistance mechanisms against TKIs in GBM. The mechanisms responsible for TKI refractoriness in GBMs are divided into 2 aspects. The first includes tumor-related concerns, such as a lack of target expression, the multiplicity of targets, redundancy, the appearance of resistant cells, and tumor changes in characteristics. The second includes drug-related concerns, such as inefficient drug effects, delivery, pharmacokinetics, and intolerable side effects. A better understanding of these mechanisms is needed to develop accurate tests to predict the lack of response to TKIs and for developing novel approaches aimed at overcoming the resistance to TKIs.
      datePublished:2014-01-08T00:00:00Z
      dateModified:2014-01-08T00:00:00Z
      pageStart:198
      pageEnd:207
      sameAs:https://doi.org/10.1007/s10014-013-0174-9
      keywords:
         Glioma
         Tyrosine kinase inhibitor
         Chemoresistance
         Neurosurgery
         Neurology
         Pathology
         Oncology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10014-013-0174-9/MediaObjects/10014_2013_174_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10014-013-0174-9/MediaObjects/10014_2013_174_Fig2_HTML.gif
      isPartOf:
         name:Brain Tumor Pathology
         issn:
            1861-387X
            1433-7398
         volumeNumber:31
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Japan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mitsutoshi Nakada
            affiliation:
                  name:Kanazawa University
                  address:
                     name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daisuke Kita
            affiliation:
                  name:Kanazawa University
                  address:
                     name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Takuya Watanabe
            affiliation:
                  name:Kanazawa University
                  address:
                     name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yutaka Hayashi
            affiliation:
                  name:Kanazawa University
                  address:
                     name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jun-ichiro Hamada
            affiliation:
                  name:Kanazawa University
                  address:
                     name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Brain Tumor Pathology
      issn:
         1861-387X
         1433-7398
      volumeNumber:31
Organization:
      name:Springer Japan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kanazawa University
      address:
         name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Kanazawa University
      address:
         name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Kanazawa University
      address:
         name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Kanazawa University
      address:
         name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Kanazawa University
      address:
         name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mitsutoshi Nakada
      affiliation:
            name:Kanazawa University
            address:
               name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daisuke Kita
      affiliation:
            name:Kanazawa University
            address:
               name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      name:Takuya Watanabe
      affiliation:
            name:Kanazawa University
            address:
               name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      name:Yutaka Hayashi
      affiliation:
            name:Kanazawa University
            address:
               name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      name:Jun-ichiro Hamada
      affiliation:
            name:Kanazawa University
            address:
               name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
      name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
      name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
      name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
      name:Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.99s.

LINK . SPRINGER . COM {}